Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center

Author:

Kern W V1,Andriof E1,Oethinger M1,Kern P1,Hacker J1,Marre R1

Affiliation:

1. Section of Infectious Diseases and Clinical Immunology, University Hospital and Medical Center, Germany.

Abstract

Prophylactic treatment with fluoroquinolones of patients with profound neutropenia has been found to be useful for preventing gram-negative bacteremia and has become a standard preventive-therapy strategy in many cancer centers, but the development of bacterial resistance is a cause of concern. During the past few years, we have observed an increasing number of patients with leukemia from whom fluoroquinolone-resistant strains of Escherichia coli were isolated. The increase was significant in this patient population, and among patients with other underlying diseases, the rates of isolation of such strains per number of discharges were significantly lower and did not increase. Most of the leukemia case patients (16 of 19) had been pretreated with an oral quinolone (ofloxacin), with cumulative doses until the first isolation of a resistant E. coli strain ranging from 0 to 97.8 g (median, 14.4 g). Repeated isolation of such strains was seen in 8 of 17 patients during a follow-up period of > or = 4 weeks and in 1 of 6 patients during a follow-up period of > or = 16 weeks. Ten patients developed bacteremia (mortality, 1 of 10). On the basis of the number of patients with leukemia admitted to the hematology-oncology service, the incidence of bacteremia caused by fluoroquinolone-resistant E. coli increased from < 0.5% in 1988-1989 and 0.8% in 1990-1991 to 4.5% in 1992-1993 (P < 0.01). MICs for nine isolates obtained from cultures of blood from different patients ranged between 8 and 16 microgram/ml (ciprofloxacin and PD 131628), 8 and 32 microgram/ml (ofloxacin and BAY Y 3118), and 16 and 32 microgram/ml (sparfloxacin) and indicated resistance to trimethoprim-sulfamethoxazole, ampicillin, doxycycline, and chloramphenicol. Of nine isolates obtained from cultures of blood from different patients and that were subjected to genomic DNA typing by pulsed-field gel electrophoresis of XbaI digests, seven were typeable. Among these, four different genotypes were identified, suggesting both the independent development and the horizontal spread of resistant clones of E. coli.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference59 articles.

1. Clinical isolate of Citrobacter freundii highly resistant to new quinolones;Aoyama H.;Amtimicrob. Agents Chemother.,1988

2. Norfloxacin resistance in a clinical isolate of Escherichia coli;Aoyama H.;Antimicrob. Agents Chemother.,1987

3. Arduino S. T. Veron H. Villar and M. Dictar. 1992. Rapid increase of resistance to fluoroquinolones in clinical isolates of Escherichia coli. Program Abstr. 32nd Intersci. Conf. Antimicrob. Agents Chemother. abstr. 635.

4. Arning M. H. H. Wolf C. Aul A. Heyll Ri E. Scharf and W. Schneider. 1990. Infection prophylaxis in neutropenic patients with acute leukemia-a randomized comparative study with ofloxacin ciprofloxacin and co-trimoxazole/colistin. J. Antimicrob. Chemother. 26(Suppl. D):137-142.

5. Carratala J. A. Fernandez-Sevilla F. Tubau M. Garcia M. Callis and F. Gudiol. 1992. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic cancer patients receiving prophylactic norfloxacin. Program Abstr. 32nd Intersci. Conf. Antimicrob. Agents Chemother. abstr. 1504.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3